{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Hanafin PO"],"funding":["NIAID NIH HHS","National Institutes of Health","NIH HHS"],"pagination":["841-852"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12353974"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["118(4)"],"pubmed_abstract":["Polymyxins are used against highly resistant Gram-negative pathogens, and nephrotoxicity (acute kidney injury, AKI) is the major dose-limiting adverse effect. We aimed to develop a well-informed population pharmacokinetic/toxicodynamic (PK/TD) model using the largest polymyxin B-treated critically ill patient population studied to inform polymyxin B dosing strategies. Critically ill patients receiving intravenous polymyxin B for at least 48 hours were enrolled in an observational study. Serum creatinine (SCr) concentrations were collected from electronic medical records. PK/TD analysis and Monte Carlo simulations were performed to determine the probability of AKI, P(AKI), for clinically relevant treatments. Patients (N = 117) aged 18-94 received intravenous polymyxin B (1.33-6.00 mg/kg/day"],"journal":["Clinical pharmacology and therapeutics"],"pubmed_title":["Population Pharmacokinetic/Toxicodynamic Model for Polymyxin B in Critically Ill Patients to Identify the Risk of Nephrotoxicity."],"pmcid":["PMC12353974"],"funding_grant_id":["R01 AI119446"],"pubmed_authors":["Bolon M","Purcell AW","Li J","Cherng BPZ","Zavascki AP","Nation RL","Kubin CJ","Wang J","Kwa A","Shah J","Wang L","Yin MT","Mahadevan R","Kaye KS","Rao GG","Scheetz MH","Sandri AM","Hanafin PO","Calfee DP","Pogue JM"],"additional_accession":[]},"is_claimable":false,"name":"Population Pharmacokinetic/Toxicodynamic Model for Polymyxin B in Critically Ill Patients to Identify the Risk of Nephrotoxicity.","description":"Polymyxins are used against highly resistant Gram-negative pathogens, and nephrotoxicity (acute kidney injury, AKI) is the major dose-limiting adverse effect. We aimed to develop a well-informed population pharmacokinetic/toxicodynamic (PK/TD) model using the largest polymyxin B-treated critically ill patient population studied to inform polymyxin B dosing strategies. Critically ill patients receiving intravenous polymyxin B for at least 48 hours were enrolled in an observational study. Serum creatinine (SCr) concentrations were collected from electronic medical records. PK/TD analysis and Monte Carlo simulations were performed to determine the probability of AKI, P(AKI), for clinically relevant treatments. Patients (N = 117) aged 18-94 received intravenous polymyxin B (1.33-6.00 mg/kg/day","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Oct","modification":"2026-06-03T02:54:44.709Z","creation":"2026-04-23T03:13:12.784Z"},"accession":"S-EPMC12353974","cross_references":{"pubmed":["40524377"],"doi":["10.1002/cpt.3729"]}}